Martina Benešová-Schäfer česká jaderná chemička
Benes̆ová, Martina
Benešová, Martina, 1988-
VIAF ID: 62168590750018222741 (Personal)
Permalink: http://viaf.org/viaf/62168590750018222741
Preferred Forms
4xx's: Alternate Name Forms (3)
5xx's: Related Names (3)
- 510 2 _ ‡a Deutsches Krebsforschungszentrum ‡e Affiliation
- 551 _ _ ‡a Heidelberg
- 551 _ _ ‡a Ostrau ‡g Mähren
Works
Title | Sources |
---|---|
[¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. | |
(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. | |
18F-AzaFol for Detection of Folate Receptor-β Positive Macrophages in Experimental Interstitial Lung Disease-A Proof-of-Concept Study | |
18th European Symposium on Radiopharmacy and Radiopharmaceuticals | |
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. | |
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC | |
Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC. | |
Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer | |
Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for Cu-Based PET Imaging | |
Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals | |
Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity | |
Development of PSMA-1007 - Related Series of 18F-Labeled Glu-ureido type PSMA inhibitors | |
Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers | |
Implementation of a new separation method to produce qualitatively improved 64 Cu | |
In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs | |
Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice | |
Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors | |
New 55Co-labeled Albumin-Binding Folate Derivatives as Potential PET Agents for Folate Receptor Imaging | |
Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. | |
Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates-new perspectives for folate receptor-targeted radionuclide therapy | |
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. | |
Sc as useful β-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes | |
Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals. | |
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. | |
Therapeutic Radiometals Beyond 177Lu and 90Y: Production and Application of Promising α-Particle, β--Particle, and Auger Electron Emitters. | |
Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2 |